Literature DB >> 8668202

Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.

D Parry1, G Peters.   

Abstract

Altered expression or function of the p16CDKN2 tumor suppressor gene on chromosome 9p21 occurs in a wide range of human tumors, and mutations in the gene have been shown to segregate with familial predisposition to malignant melanoma. We have used a variety of assays to examine the functional properties of tumor-associated alleles, including eight premature termination mutants, eight missense mutants, and three isoforms of p16 initiated at different amino-terminal methionine codons. The amino- and carboxy-terminal domains of the protein, outside the ankyrin-like repeats, appeared to be dispensable, but the majority of the premature termination mutations led to loss of function. Of the missense mutations tested, four displayed clear loss of function whereas two behaved like the wild type under all conditions tested. The remaining two mutations, a G-to-W mutation at position 101 (Gl01W) and V126D, both of which are associated with familial melanoma, were found to be temperature sensitive for binding to Cdk4 and Cdk6 in vitro, for inhibiting cyclin D1-Cdk4 in a reconstituted pRb-kinase assay, and for increasing the proportion of G1-phase cells following transfection. These findings clarify previous disparities and argue strongly that p16CDKN2 is a bona fide tumor suppressor associated with familial melanoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8668202      PMCID: PMC231381          DOI: 10.1128/MCB.16.7.3844

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  62 in total

Review 1.  Inhibitors of mammalian G1 cyclin-dependent kinases.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1995-05-15       Impact factor: 11.361

2.  CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.

Authors:  Q Liu; S Neuhausen; M McClure; C Frye; J Weaver-Feldhaus; N A Gruis; K Eddington; M J Allalunis-Turner; M H Skolnick; F K Fujimura
Journal:  Oncogene       Date:  1995-03-16       Impact factor: 9.867

3.  Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias.

Authors:  J Hebert; J M Cayuela; J Berkeley; F Sigaux
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

4.  Mutations and altered expression of p16INK4 in human cancer.

Authors:  A Okamoto; D J Demetrick; E A Spillare; K Hagiwara; S P Hussain; W P Bennett; K Forrester; B Gerwin; M Serrano; D H Beach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

5.  Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.

Authors:  M Ohta; H Nagai; M Shimizu; D Rasio; D Berd; M Mastrangelo; A D Singh; J A Shields; C L Shields; C M Croce
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

6.  Loss of heterozygosity of chromosome 9p21 is associated with the immortal phenotype of neoplastic human head and neck keratinocytes.

Authors:  O Loughran; K G Edington; I J Berry; L J Clark; E K Parkinson
Journal:  Cancer Res       Date:  1994-10-01       Impact factor: 12.701

7.  Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck.

Authors:  S Y Zhang; A J Klein-Szanto; E R Sauter; M Shafarenko; S Mitsunaga; T Nobori; D A Carson; J A Ridge; T L Goodrow
Journal:  Cancer Res       Date:  1994-10-01       Impact factor: 12.701

8.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.

Authors:  C Caldas; S A Hahn; L T da Costa; M S Redston; M Schutte; A B Seymour; C L Weinstein; R H Hruban; C J Yeo; S E Kern
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

9.  Deletion of p16 and p15 genes in brain tumors.

Authors:  J Jen; J W Harper; S H Bigner; D D Bigner; N Papadopoulos; S Markowitz; J K Willson; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

10.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.

Authors:  A Kamb; D Shattuck-Eidens; R Eeles; Q Liu; N A Gruis; W Ding; C Hussey; T Tran; Y Miki; J Weaver-Feldhaus
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

View more
  16 in total

1.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.

Authors:  P Ciotti; J P Struewing; M Mantelli; A Chompret; M F Avril; P L Santi; M A Tucker; G Bianchi-Scarrà; B Bressac-de Paillerets; A M Goldstein
Journal:  Am J Hum Genet       Date:  2000-06-22       Impact factor: 11.025

Review 2.  The ankyrin repeat as molecular architecture for protein recognition.

Authors:  Leila K Mosavi; Tobin J Cammett; Daniel C Desrosiers; Zheng-Yu Peng
Journal:  Protein Sci       Date:  2004-06       Impact factor: 6.725

Review 3.  Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.

Authors:  Lei Miao; C Michael Lin; Leaf Huang
Journal:  J Control Release       Date:  2015-08-12       Impact factor: 9.776

4.  Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb.

Authors:  S A Ezhevsky; H Nagahara; A M Vocero-Akbani; D R Gius; M C Wei; S F Dowdy
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

Review 5.  Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis.

Authors:  Thea D Tlsty; Yongping G Crawford; Charles R Holst; Colleen A Fordyce; Jianmin Zhang; Kimberly McDermott; Krystyna Kozakiewicz; Mona L Gauthier
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-07       Impact factor: 2.673

6.  Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors.

Authors:  D Parry; D Mahony; K Wills; E Lees
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

7.  Assessment of functional effects of unclassified genetic variants.

Authors:  Fergus J Couch; Lene Juel Rasmussen; Robert Hofstra; Alvaro N A Monteiro; Marc S Greenblatt; Niels de Wind
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

8.  A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL).

Authors:  Mark Harland; Alisa M Goldstein; Kairen Kukalizch; Claire Taylor; David Hogg; Susana Puig; Celia Badenas; Nelleke Gruis; Jeanet ter Huurne; Wilma Bergman; Nicholas K Hayward; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Maria Teresa Landi; Giovanna Bianchi Scarra; Paola Ghiorzo; Peter A Kanetsky; David Elder; Graham J Mann; Elizabeth A Holland; D Timothy Bishop; Julia Newton Bishop
Journal:  Eur J Cancer       Date:  2008-04-03       Impact factor: 9.162

9.  INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence.

Authors:  Sharon Brookes; Janice Rowe; Margarida Ruas; Susana Llanos; Paula A Clark; Martine Lomax; Marion C James; Radost Vatcheva; Stewart Bates; Karen H Vousden; David Parry; Nelleke Gruis; Nico Smit; Wilma Bergman; Gordon Peters
Journal:  EMBO J       Date:  2002-06-17       Impact factor: 11.598

10.  Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.

Authors:  Noah C Jenkins; Jae Jung; Tong Liu; Megan Wilde; Sheri L Holmen; Douglas Grossman
Journal:  J Invest Dermatol       Date:  2012-11-29       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.